Nutra Pharma Corp., a biotechnology holding company that owns rights to patents and intellectual property related to the development of drugs for HIV and Multiple Sclerosis (MS), today announced that it has engaged Eno Research and Development, Inc. (ERDI) to study RPI-78M.
RPI-78M is the lead drug candidate of Nutra Pharma's minority holding, ReceptoPharm, Inc. and is being studied in preclinical assays for its efficacy in treating Multiple Sclerosis. ERDI will measure the effect of RPI-78M on gene expression using cDNA microarray technology and identify any potentially unique changes in gene expression that may be caused by the therapy.
"Much effort has gone into identifying genes that cause or contribute to the disease process of MS," commented James Flowers, ERDI's President and Chief Scientific Officer. "Still, it is unknown how many of these genes actually relate to the pathogenesis of this disease," he continued. "RPI-78M may allow us to better elucidate the underlying mechanisms of MS while evaluating its potential therapeutic benefits."
ERDI will conduct this research through the end of 2004.
"We are very excited about the talent and experience that ERDI brings to Nutra Pharma and ReceptoPharm," said Rik J. Deitsch, Nutra Pharma's Chief Executive Officer. "The scientific staff of ERDI has the expertise necessary to provide the information that we need to move RPI-78M into the clinical setting," he added.
"ERDI adds a critical component to the work that we have already accomplished," commented Paul F. Reid, Ph.D., ReceptoPharm's Chief Executive Officer. "By evaluating what's occurring in the cells of MS patients at a genetic level, we hope to get a better idea as to the mechanism of RPI-78M," he concluded.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Engaging Eno Research and Development, Inc. to study RPI-78M should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.